GLOW 70 is the “finishing touch for those who are already lean” — a blend developed for the post–body transformation phase, focused on improving skin quality, firmness, and density, reducing the appearance of “loose/empty skin” and promoting a more even, rejuvenated look.
Its action is centred on remodelling the Extracellular Matrix (ECM): high-concentration GHK-Cu is associated with modulation of gene expression linked to collagen and elastin; TB-500 with cell migration and skin renewal; and BPC-157 with support for microcirculation and the reparative response.
In well-designed protocols, the result is an aesthetic finish with greater structure, elasticity, and radiance.
Key Benefits
- Firmer, more radiant skin
- Visibly more youthful appearance
- Restored elasticity (a “more filled” skin feel)
- proved dermal density and a more even texture
GLOW 70 is the “finishing touch for those who are already lean” — a blend developed for the post–body transformation phase, focused on improving skin quality, firmness, and density, reducing the appearance of “loose/empty skin” and promoting a more even, rejuvenated look.
Its action is centred on remodelling the Extracellular Matrix (ECM): high-concentration GHK-Cu is associated with modulation of gene expression linked to collagen and elastin; TB-500 with cell migration and skin renewal; and BPC-157 with support for microcirculation and the reparative response.
In well-designed protocols, the result is an aesthetic finish with greater structure, elasticity, and radiance.
Key Benefits
– Firmer, more radiant skin
– Visibly more youthful appearance
– Restored elasticity (a “more filled” skin feel)
– proved dermal density and a more even texture
Technical Details
Item Weight
Product Dimensions
Item model number
Item Package Quantity
Number of Handles
Batteries Required?
GLOW (blend)
Vial content: 70 mg total
Proposed reconstitution: 3.0 mL
Syringe: U-100 insulin syringe
Resulting concentration
Desired doses
2.0 mg dose
2.5 mg dose
Both fall between 8 and 11 IU, which is:
Retatrutide is a triple agonist of GLP-1, GIP, and glucagon. This combination works in an integrated manner to reduce appetite and increase satiety, improve glycaemic homeostasis, and promote greater energy expenditure/thermogenesis via activity at the glucagon receptor.
This product is supplied as a pack of 4 vials, each containing 10 mg.
Key Benefits
Marked reduction in body weight in clinical studies, with high-impact results in obesity.
Improved glycaemic control and cardiometabolic markers (e.g., inflammatory lipids and blood pressure reported in readouts).
Reduced liver fat and improvements associated with metabolic liver disease (MASLD/MASH) in a Phase 2a study.
Quality of weight loss (body composition): evidence suggests a greater reduction in fat mass, without a disproportionate increase in lean mass loss, in body-composition sub-studies.
Tirzepatide is a dual agonist of GIP and GLP-1 receptors, acting in an integrated way across incretin pathways. It increases insulin secretion in a glucose-dependent manner and improves glycaemic regulation (reducing peaks and variability). It also acts on appetite/satiety centres, contributing to reduced food intake.
This product is supplied as a pack of 4 vials, each containing 15 mg.
Key Benefits
Significant reduction in body weight in studies involving people with obesity/overweight (results depend on dose, duration, and adherence).
Robust improvement in glycaemic control (HbA1c) in people with type 2 diabetes, with dose-dependent reductions observed in clinical trials.
Cardiometabolic improvements associated with weight loss and incretin pathway activity.
Maintenance of weight loss with continued treatment, demonstrating sustained outcomes when use is maintained within protocol (in maintenance trials).
Intelligent metabolic regulation for consistent weight loss.
Tirzepatide is a dual agonist of GIP and GLP-1 receptors, acting in an integrated way across incretin pathways.It increases insulin secretion in a glucose-dependent manner and improves glycaemic regulation (reducing peaks and variability).
It acts on appetite/satiety centres, helping to reduce food intake and supporting adherence to body recomposition strategies.
Key Benefits
Mechanism of Action
Retatrutide is a triple agonist of GLP-1, GIP, and glucagon receptors. This combination works in an integrated manner to reduce appetite and increase satiety, improve glycaemic homeostasis, and promote greater energy expenditure/thermogenesis via activity at the glucagon receptor.
Key Benefits
– Marked reduction in body weight in clinical studies, with high-impact results in obesity.
– Improved glycaemic control and cardiometabolic markers (e.g., inflammatory lipids and blood pressure reported in readouts).
– Reduction in liver fat and improvements associated with metabolic liver disease (MASLD/MASH) in a Phase 2a study.
– Quality of weight loss (body composition): evidence suggests a greater reduction in fat mass, without a disproportionate increase in lean mass loss, in body-composition sub-studies.
– Tolerability profile consistent with the incretin class, with gastrointestinal events most commonly reported in studies (e.g., nausea, diarrhoea, and constipation).
